Bruce Leigh Riser

USPTO Granted Patents = 9 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 1.2

ph-index = 3

Forward Citations = 16(Granted Patents)

Company Filing History:

7 out of 48

Rosalind Franklin University of Medicine and Science

patents

2 out of 2,480

Baxter International Inc.

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12024544 - CCN3 and CCN3 peptides and analogs thereof for therapeutic use (2024-07-02),

2. 11505582 - CCN3 and CCN3 peptides and analogs thereof for therapeutic use (2022-11-22),

3. 10351608 - CCN3 and CCN3 peptides and analogs thereof for therapeutic use (2019-07-16),

4. 10028906 - Method and kit for treating a solid tumor and associated desmoplasia (2018-07-24),

5. 9114112 - CCN3 and CCN3 peptides and analogs thereof for therapeutic uses (2015-08-25),

6. 8518395 - CCN3 peptides and analogs thereof for therapeutic use (2013-08-27),

7. 8273378 - Dialysis solutions containing pyrophosphates (2012-09-25),

8. 7780949 - Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases (2010-08-24),

9. 7658952 - Dialysis solutions containing pyrophosphates (2010-02-09),

Title: Bruce Leigh Riser: Innovator in Therapeutic Applications

Introduction

Bruce Leigh Riser is a notable inventor based in Kenosha, Wisconsin. He has made significant contributions to the field of therapeutic applications, holding a total of nine patents. His work focuses on innovative methods for treating various pathologies through the use of specific proteins and peptides.

Latest Patents

Among his latest patents is the invention related to CCN3 and CCN3 peptides and analogs for therapeutic use. This invention provides a method for treating human patients by administering an effective amount of agents selected from a group that includes native full-length CCN3 proteins, analog CCN3 full-length proteins with substituted cysteine residues, and native peptide fragments with specific amino acid lengths. The invention emphasizes the potential of these agents in addressing various health conditions.

Career Highlights

Bruce has worked with prominent organizations such as Rosalind Franklin University of Medicine and Science and Baxter International Inc. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical therapies.

Collaborations

Throughout his career, Bruce has collaborated with notable colleagues, including Paul Zieske and Sujatha Karoor. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapeutic solutions.

Conclusion

Bruce Leigh Riser's contributions to the field of therapeutic applications through his innovative patents highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.